*Duke Eye Center †Department of Plastic Surgery, Duke University, Durham, NC.
J Glaucoma. 2014 Feb;23(2):e91-7. doi: 10.1097/IJG.0b013e3182955d73.
To retrospectively evaluate the safety and efficacy of an Ahmed glaucoma valve (AGV) modified with a polyethylene shell (M4) to reduce the fibrotic reaction around the drainage plate compared with the S2 and FP7 models in patients with glaucoma.
The medical records of patients who underwent implantation of the AGV FP7, S2, and M4 were reviewed. The primary outcome measure was cumulative probability of success, defined as an intraocular pressure (IOP) between 5 and 18 mm Hg and >20% reduction of IOP without loss of light perception, need for additional IOP-lowering surgical procedures, or removal of AGV.
Seventy-six, 38, and 40 eyes received the FP7, S2, and M4 with a mean follow-up time of 578±157, 662±186, and 504±158 days, respectively. The mean IOP was reduced from 31.0±10.6 to 13.9±5.5 mm Hg in the FP7 group, 33.5±12.1 to 15.8±8.1 mm Hg in the S2 group, and 27.0±12.0 to 15.0±4.0 mm Hg in the M4 group at 1 year (P=0.31). At 1 year, the cumulative probability of success was 70%, 66%, and 80% and at 18 months, 61%, 53%, and 52% in the FP7, S2, and M4 groups, respectively (P=0.99). Complications were similar among groups.
No significant difference was observed between the AGV M4, FP7, and S2 at 1 year. Additional follow-up is required to determine its long-term safety profile and efficacy.
回顾性评估改良型 Ahmed 青光眼引流阀（AGV）与 S2 和 FP7 模型相比，通过在引流盘周围使用聚乙烯壳（M4）来减少纤维组织反应的安全性和有效性，该改良型 AGV 应用于青光眼患者。
回顾性分析接受 AGV FP7、S2 和 M4 植入术患者的病历。主要观察指标是累积成功率，定义为眼压（IOP）在 5 至 18mmHg 之间，IOP 降低幅度超过 20%，无光感丧失，无需进行额外的眼压降低手术或移除 AGV。
76、38 和 40 只眼分别接受了 FP7、S2 和 M4 治疗，平均随访时间分别为 578±157、662±186 和 504±158 天。FP7 组的平均 IOP 从 31.0±10.6mmHg 降低至 13.9±5.5mmHg，S2 组从 33.5±12.1mmHg 降低至 15.8±8.1mmHg，M4 组从 27.0±12.0mmHg 降低至 15.0±4.0mmHg，1 年后各组的 IOP 均降低（P=0.31）。1 年后，FP7、S2 和 M4 组的累积成功率分别为 70%、66%和 80%，18 个月时分别为 61%、53%和 52%（P=0.99）。各组的并发症相似。
FP7、S2 和 M4 在 1 年内没有显著差异。需要进一步随访以确定其长期安全性和疗效。
